22 research outputs found

    Stat1-Dependent, p53-Independent Expression of p21(waf1) Modulates Oxysterol-Induced Apoptosis

    Full text link
    7-Ketocholesterol (7kchol) is prominent in atherosclerotic lesions where apoptosis occurs. Using mouse fibroblasts lacking p53, p21(waf1), or Stat1, we found that optimal 7kchol-induced apoptosis requires p21(waf1) and Stat1 but not p53. Findings were analogous in a human cell system. Apoptosis was restored in Stat1-null human cells when wild-type Stat1 was restored. Phosphorylation of Stat1 on Ser(727) but not Tyr(701) was essential for optimum apoptosis. A neutralizing antibody against beta interferon (IFN-β) blunted Ser(727) phosphorylation and apoptosis after 7kchol treatment; cells deficient in an IFN-β receptor subunit exhibited blunted apoptosis. IFN-β alone did not induce apoptosis; thus, 7kchol-induced release of IFN-β was necessary but not sufficient for optimal apoptosis. In Stat1-null cells, expression of p21(waf1) was much less than in wild-type cells; introducing transient expression of p21(waf1) restored apoptosis. Stat1 and p21(waf1) were essential for downstream apoptotic events, including cytochrome c release from mitochondria and activation of caspases 9 and 3. Our data reveal key elements of the cellular pathway through which an important oxysterol induces apoptosis. Identification of the essential signaling events that may pertain in vivo could suggest targets for therapeutic intervention

    Gender Differences in Physicians' Financial Ties to Industry: A Study of National Disclosure Data.

    Full text link
    Academic literature extensively documents gender disparities in the medical profession with regard to salary, promotion, and government funded research. However, gender differences in the value of financial ties to industry have not been adequately studied despite industry's increasing contribution to income and research funding to physicians in the U.S.We analyzed publicly reported financial relationships among 747,603 physicians and 432 pharmaceutical, device and biomaterials companies. Demographic and payment information were analyzed using hierarchical regression models to determine if statistically significant gender differences exist in physician-industry interactions regarding financial ties, controlling for key covariates. In 2011, 432 biomedical companies made an excess of 17,991,000inpaymentsto220,908physicians.Ofthesephysicians,75.117,991,000 in payments to 220,908 physicians. Of these physicians, 75.1% were male. Female physicians, on average, received fewer total dollars (-3,598.63, p<0.001) per person than men. Additionally, female physicians received significantly lower amounts for meals (-41.80,p<0.001),education(41.80, p<0.001), education (-1,893.14, p<0.001), speaker fees (-2,898.44,p<0.001),andsponsoredresearch(2,898.44, p<0.001), and sponsored research (-15,049.62, p=0.05). For total dollars, an interaction between gender and institutional reputation was statistically significant, implying that the differences between women and men differed based on industry's preference for an institution, with larger differences at higher reputation institutions.Female physicians receive significantly lower compensation for similarly described activities than their male counterparts after controlling for key covariates. As regulations lead to increased transparency regarding these relationships, efforts to standardize compensation should be considered to promote equitable opportunities for all physicians
    corecore